21 CFR 606.122 - Circular of information.
prev | next
A circular of information must be available for distribution if the product is intended for transfusion. The circular of information must provide adequate directions for use, including the following information:
(d) A description of the product, its source, and preparation, including the name and proportion of the anticoagulant used in collecting the Whole Blood from each product is prepared.
(e) A statement that the product was prepared from blood that was found negative when tested for communicable disease agents, as required under § 610.40 of this chapter (include each test that was performed).
(f) The statement: “Warning: The risk of transmitting infectious agents is present. Careful donor selection and available laboratory tests do not eliminate the hazard.”
(g) The names of cryoprotective agents and other additives that may still be present in the product.
(i) The use of the product, indications, contradications, side effects and hazards, dosage and administration recommendations.
(1) Instructions to administer a suitable plasma volume expander if Red Blood Cells are substituted when Whole Blood is the indicated product.
(2) Instructions to begin administration as soon as possible, but not more than 4 hours after entering the container.
(1) A warning against further processing of the frozen product if there is evidence of breakage or thawing.
(3) When applicable, instructions to begin administration of the product within a specified time after thawing.
(5) A statement that this product has the same risk of transmitting infectious agents as Whole Blood; other plasma volume expanders without this risk are available for treating hypovolemia.
(1) A statement that the average potency is 80 or more International Units of antihemophilic factor.
(2) The statement: “Usually contains at least 150 milligrams of fibrinogen”; or, alternatively, the average fibrinogen level determined by assay of representative units.
(3) A warning against further processing of the product if there is evidence of breakage or thawing.
(4) Instructions to thaw the product for no more than 15 minutes at a temperature of between 30 and 37 °C.
(5) Instructions to store at room temperature after thawing and to begin administration as soon as possible but no more than 4 hours after entering the container or after pooling and within 6 hours after thawing.
(7) Adequate instructions for pooling to ensure complete removal of all concentrated material from each container.
(8) The statement: “Good patient management requires monitoring treatment responses to Cryoprecipitated AHF transfusions with periodic plasma factor VIII or fibrinogen assays in hemophilia A and hypofibrinogenemic recipients, respectively.”
Title 21 published on 2013-04-01
no entries appear in the Federal Register after this date.